News for Surmodics, Inc. (SRDX)

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Surmodics (SRDX) has forecasted its fiscal 2025 revenue to be between $114 million and $117 million, which reflects a decline of 10% to 7% from fiscal 2024 figu

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial

Surmodics (SRDX) announced its financial results for the second quarter of fiscal 2025, reporting a total revenue of $28.09 million. This figure fell short of t

Surmodics (SRDX) reported a 12% year-over-year revenue decrease to $28.1 million in Q2 FY 2025. The company experienced a GAAP net loss of $5.2 million

Revenue: $28.1 million, falling short of the estimated $32.23 million and marking a 12% decrease year-over-year.GAAP Net Loss: $(5.2) million, a significant de

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that sec

Shares of Surmodics Inc (SRDX) surged 4.45% in mid-day trading on Apr 28. The stock reached an intraday high of $30.97, before settling at $30.77, up from i

RoboMarkets has announced the addition of more than 1,160 new assets to its R StocksTrader platform, strengthening its position as a regulated multi-asset

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the comm

On December 31, 2024, Barclays PLC executed a notable transaction by acquiring 950,308 shares of Surmodics Inc (SRDX) at a traded price of $39.6 per share. This

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the succ

Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SurModics (SRDX) delivered earnings and revenue surprises of 50% and 10.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Surmodics (SRDX) drops 5.8% as FTC reviews planned sale to GTCR, citing concerns about potential creation of dominating medical device coatings maker.